Usefulness of heart rale variability in predicting drug efficacy (metoprolol vs diltiazem) in patients with stable angina pectoris

We investigated whether analysis of heart rate (HR) variability may be used to predict the efficacy of drug treatment of myocardial ischemia. In a double-blind, crossover study, 28 patients with stable angina pectoris, proven coronary artery disease, and myocardial ischemia during Holter monitoring received metoprolol controlled-release 200 mg once daily and diltiazem 60 mg 4 times daily. After a placebo run-in phase and after each treatment period, 72-hour Holter recordings were obtained for HR variability and ST-segment analysis. At baseline, the total duration of myocardial ischemia was 11.4 ± 13.9 minutes (mean ± SD per 24 hours), and the total number of episodes was 2.2 ± 2.3. Metoprolol significantly reduced the total duration of ischemia by −8.7 minutes (95% Cl −14.5 to −2.8) and the total number of episodes by −1.9 (−2.9 to −0.8) in patients with a low SD of normal-to-normal intervals at baseline (SDNN), using the median value of 50 ms as a cut-off value. In contrast, significant treatment effects were not observed in patients with a high SDNN at baseline. Similar results were obtained using base-line total power or low-frequency power, but not when using baseline heart rate. Diltiazem reduced the total duration of ischemia by −4.9 minutes (−9.7 to −0.1), but not the number of episodes. Moreover, in contrast to metoprolol, efficacy of diltiazem was not related to baseline HR variability. In conclusion, patients with reduced HR variability at baseline responded to treatment with metoprolol. This differential pattern was not observed with diltiazem. Our results, therefore, suggest that analysis of HR variability may be useful in selecting patients who will benefit from treatment with β blockers.